Furthermore, FFAR2 deletion, pharmaceutical inhibition or L-Arginine supplementation reverse the immunosuppressive microenvironment and promote T cell infiltration and anti-tumor response significantly, which have the great potential to be a novel target to enhance the outcomes of cancer immunotherapy. Here, FFAR2 is linked to cancer.